- First retail sales in US commence in beauty capital of
Los Angeles on November 20, targeting US skincare market
- Initial distribution to include partnership with leading
lifestyle media and retail brand Cannabis Now
- Activation at Cannabis Now's high-traffic Los Angeles location to target affluent,
trendy audience of beauty and cannabis consumers
- Company to support sales through comprehensive marketing and
branding campaign, including content to reach Cannabis Now's
4.2M audience
- Launch to kick off with experiential event on Nov. 20 at Cannabis Now flagship store
- US skincare market estimated at US $20
billion in 2018 (Source: Euromonitor)
TORONTO, Nov. 18, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America, today announced the official
launch of the Company's Kuida brand in the United States. Beginning this Wednesday, November 20, Kuida's line of CBD
skincare products will become available for purchase to US
consumers at retail, initially in Los
Angeles, before a planned expansion in priority US states
where sale of hemp-derived CBD is permitted.
In the California market, Kuida
will initially be distributed and sold through a partnership with
leading lifestyle media and retail brand, Cannabis Now. With a
prime flagship location in Los
Angeles and an expanding retail network including three
planned stores across major US cities, Cannabis Now offers a
selection of non-THC health and wellness products in an
experiential retail environment designed to educate both
experienced and new cannabis consumers. Through an exclusive
activation at Cannabis Now's high-traffic Beverly Hills location, the Kuida brand will
target an affluent, on-trend audience of beauty and cannabis
consumers, influencers, and professionals across Los Angeles as well as the wider US
market.
"We are incredibly proud to be the first Colombian brand to
introduce legal CBD products in the US market," stated Elsa Navarro, Skin Unit Director of Khiron Life
Sciences. "As we enter the United
States market and commence sales, we bring proven success in
brand building, a scientifically-backed, GMP lab made product, and
a powerful branding and marketing campaign that resonates with
consumers. As a result, we find ourselves in a strong position to
reach consumers and gain market share in the fast-growing US
skincare market."
Eugenio Garcia, CEO and Founder
at Cannabis Now comments: "At Cannabis Now, we are disrupting the
cannabis retail space to introduce first-of-its-kind experiential
and education-focused experiences. Khiron shares our commitment to
innovation and high-quality products that help improve the consumer
experience, and Kuida is an ideal addition to our retail
marketplace. We are very excited to share Kuida with our customer
base and wide following in the US."
In addition to in-store programming, the Company will also
support the retail pop-up and drive sales through a comprehensive
marketing campaign spanning mass media, experiential activations,
social media, and influencer partnerships. Kuida will further
collaborate with Cannabis Now on educational content as well as
print and digital advertising, leveraging the brand's media
offering to reach its following of 4.2 million US consumers.
The introduction of Kuida in the
United States will kick off with a launch event on
Wednesday, November 20th
at Cannabis Now with the Khiron executive team, beauty experts and
lifestyle influencers. Investors are invited to experience Kuida
for themselves and to join Khiron Life Sciences as they celebrate
this momentous milestone!
Kuida Kick-Off Event
Details
Wednesday, November
20th
7:00 PM
Cannabis Now
8495 W. 3rd Street
Los Angeles
To RSVP: eventos@khiron.ca
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is positioned to be the dominant integrated cannabis company
in Latin America. Khiron has core
operations in Latin America and is
fully licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. The company delivers best in class regulatory
compliance, has the first approved set of CBD cosmetic products on
shelf in Colombia, and is currently facilitating testing to
meet and surpass all license requirements for commercial cannabis
derived products.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Further information in respect of the Company can be found
at www.khiron.ca.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-launches-kuida-brand-in-the-us-begins-first-sales-300959659.html
SOURCE Khiron Life Sciences Corp.